CliffBio
small molecule

RANOLAZINE

RANOLAZINE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameRANOLAZINE
Active ingredientRANOLAZINE
Strength500MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2019
Marketing statusDISCN

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

RANOLAZINE patent cliff — loss of exclusivity — | CliffBio